{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T08:03:30Z","timestamp":1694678610450},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00059-016-4427-3","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T08:21:38Z","timestamp":1460622098000},"page":"208-216","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Glucose-lowering therapy in type\u00a02 diabetes"],"prefix":"10.1007","volume":"41","author":[{"given":"G.","family":"Schernthaner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.-H.","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"4427_CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10354-010-0748-7","volume":"160","author":"G Schernthaner","year":"2010","unstructured":"Schernthaner G (2010) Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from aCCORD, aDVaNCE, VaDT, UKPDS, PROactive, and NICE-SUGaR. Wien Med Wochenschr 160:8\u201319","journal-title":"Wien Med Wochenschr"},{"key":"4427_CR2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP et al (2008) Action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545\u20132559","journal-title":"N Engl J Med"},{"key":"4427_CR3","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J et al (2008) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560\u20132572","journal-title":"N Engl J Med"},{"key":"4427_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T et al (2009) Intensive glucose control and complications in american veterans with type 2 diabetes. N Engl J Med 360:129\u2013139","journal-title":"N Engl J Med"},{"key":"4427_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00125-010-1933-3","volume":"54","author":"JA Johnson","year":"2011","unstructured":"Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta analysis of major trials. Diabetologia 54:25\u201331","journal-title":"Diabetologia"},{"key":"4427_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/00365510500236119","volume":"240","author":"GH Schernthaner","year":"2005","unstructured":"Schernthaner GH, Schernthaner G (2005) Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand J Clin Lab Invest Suppl 240:30\u201340","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"4427_CR7","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.108.829176","volume":"119","author":"SR Preis","year":"2009","unstructured":"Preis SR, Hwang SJ, Coady S (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:1728\u20131735","journal-title":"Circulation"},{"key":"4427_CR8","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s00125-008-1156-z","volume":"51","author":"B Carstensen","year":"2008","unstructured":"Carstensen B, Kristensen JK, Ottosen P et al (2008) The danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia 51:2187\u20132196","journal-title":"Diabetologia"},{"key":"4427_CR9","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s00125-013-3063-1","volume":"56","author":"M Lind","year":"2013","unstructured":"Lind M, Garcia-Rodriguez LA, Booth GL et al (2013) Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia 56:2601\u20132608","journal-title":"Diabetologia"},{"key":"4427_CR10","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.2337\/dc14-0096","volume":"37","author":"JL Harding","year":"2014","unstructured":"Harding JL, Shaw JE, Peeters A et al (2014) Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997\u20132010. Diabetes Care 37:2579\u20132588","journal-title":"Diabetes Care"},{"key":"4427_CR11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215\u20132222","journal-title":"Lancet"},{"key":"4427_CR12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","volume":"373","author":"M Tancredi","year":"2015","unstructured":"Tancredi M, Rosengren A, Svensson AM et al (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373:1720\u20131732","journal-title":"N Engl J Med"},{"key":"4427_CR13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2337\/dc14-1877","volume":"38","author":"G Vazquez-Benitez","year":"2015","unstructured":"Vazquez-Benitez G, Desai JR, Xu S et al (2015) Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care 38:905\u2013912","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"4427_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2337\/dcS13-2041","volume":"36","author":"B Hirshberg","year":"2013","unstructured":"Hirshberg B, Katz A (2013) Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care 36(Suppl 2):253\u2013258","journal-title":"Diabetes Care"},{"key":"4427_CR15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279\u20131289","journal-title":"Lancet"},{"key":"4427_CR16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"ORIGIN Trial Investigators","year":"2012","unstructured":"Trial Investigators ORIGIN, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319\u2013328","journal-title":"N Engl J Med"},{"key":"4427_CR17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317\u20131326","journal-title":"N Engl J Med"},{"key":"4427_CR18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327\u20131335","journal-title":"N Engl J Med"},{"key":"4427_CR19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232\u2013242","journal-title":"N Engl J Med"},{"key":"4427_CR20","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247\u20132257","journal-title":"N Engl J Med"},{"key":"4427_CR21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"4427_CR22","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","volume":"49","author":"E Erdmann","year":"2007","unstructured":"Erdmann E, Dormandy JA, Charbonnel B et al (2007) The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J\u00a0Am Coll Cardiol 49:1772\u20131780","journal-title":"J Am Coll Cardiol"},{"key":"4427_CR23","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","volume":"38","author":"R Wilcox","year":"2007","unstructured":"Wilcox R, Bousser MG, Betteridge DJ et al (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865\u2013873","journal-title":"Stroke"},{"key":"4427_CR24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.atherosclerosis.2008.03.002","volume":"202","author":"JA Dormandy","year":"2009","unstructured":"Dormandy JA, Betteridge DJ, Schernthaner G et\u00a0al (2009) Impact of peripheral arterial disease in patients with diabetes results from PROactive (PROactive 11). Atherosclerosis 202:272\u2013281","journal-title":"Atherosclerosis"},{"key":"4427_CR25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1681\/ASN.2007060678","volume":"19","author":"CA Schneider","year":"2008","unstructured":"Schneider CA, Ferrannini E, Defronzo R et al (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19:182\u2013187","journal-title":"J Am Soc Nephrol"},{"key":"4427_CR26","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T Mazzone","year":"2006","unstructured":"Mazzone T, Meyer PM, Feinstein SB et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572\u20132581","journal-title":"JAMA"},{"key":"4427_CR27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561\u20131573","journal-title":"JAMA"},{"key":"4427_CR28","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1742-1241.2009.02025.x","volume":"63","author":"G Schernthaner","year":"2009","unstructured":"Schernthaner G (2009) Pleiotropic effects of thiazolidinediones on traditional and nontraditional atherosclerotic risk factors. Int J Clin Pract 63:912\u2013929","journal-title":"Int J Clin Pract"},{"key":"4427_CR29","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","volume":"53","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:1270\u20131287","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"4427_CR30","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.2337\/dcS13-2031","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Currie CJ, Schernthaner GH (2013) Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 36(Suppl 2):S155\u2013S161","journal-title":"Diabetes Care"},{"key":"4427_CR31","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","volume":"30","author":"E Erdmann","year":"2007","unstructured":"Erdmann E, Charbonnel B, Wilcox RG (2007) Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study. Diabetes Care 30:2773\u20132778","journal-title":"Diabetes Care"},{"key":"4427_CR32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP et al (2015) Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314:265\u2013277","journal-title":"JAMA"},{"key":"4427_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00125-014-3456-9","volume":"58","author":"D Levin","year":"2015","unstructured":"Levin D, Bell S, Sund R et al (2015) Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58:493\u2013504","journal-title":"Diabetologia"},{"key":"4427_CR34","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP et al (2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17:1180\u20131193","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl B1","key":"4427_CR35","first-page":"1133","volume":"26","author":"C Wanner","year":"2015","unstructured":"Wanner C, Lachin JM, Fitchett DH et al (2015) Empagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease. J Am Soc Nephrol 26(Suppl B1):1133","journal-title":"J Am Soc Nephrol"},{"key":"4427_CR36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB et al (2009) (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193\u2013203","journal-title":"Diabetes Care"},{"key":"4427_CR37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","volume":"53","author":"G Schernthaner","year":"2010","unstructured":"Schernthaner G, Barnett AH, Betteridge DJ et\u00a0al (2010) Is the ADA\/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53:1258\u20131269","journal-title":"Diabetologia"},{"key":"4427_CR38","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","volume":"55","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. position statement of the american diabetes association (aDa) and the european association for the study of diabetes (EaSD). Diabetologia 55:1577\u20131596","journal-title":"Diabetologia"},{"key":"4427_CR39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140\u2013149","journal-title":"Diabetes Care"},{"key":"4427_CR40","first-page":"77","volume-title":"Pharmacotherapy of Diabetes: New Developments","author":"G Schernthaner","year":"2008","unstructured":"Schernthaner G, Schernthaner GH (2008) Metformin \u2013 From Devil to Angel. In: Pharmacotherapy of Diabetes: New Developments. In: CE Mogensen, editor. Wien: Springer; pp 77\u201386"},{"key":"4427_CR41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10557-008-6092-0","volume":"22","author":"CJ Bailey","year":"2008","unstructured":"Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22:215\u2013224","journal-title":"Cardiovasc Drugs Ther"},{"key":"4427_CR42","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1210\/jc.2003-030861","volume":"89","author":"G Schernthaner","year":"2004","unstructured":"Schernthaner G, Matthews DR, Charbonnel B et al (2004) Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068\u20136076","journal-title":"J Clin Endocrinol Metab"},{"key":"4427_CR43","first-page":"\u25a0","volume":"\u25a0","author":"CF Deacon","year":"2015","unstructured":"Deacon CF, Lebovitz HE (2015) A comparative review of DPP\u20114 inhibitors and Sulphonylureas. Diabetes Obes Metab . doi:10.1111\/dom.12610 [Epub ahead of print]","journal-title":"Diabetes Obes Metab"},{"key":"4427_CR44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/dom.12321","volume":"16","author":"G Schernthaner","year":"2014","unstructured":"Schernthaner G, Barnett AH, Patel S et al (2014) Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged \u2265 65 years. Diabetes Obes Metab 16:1078\u20131086","journal-title":"Diabetes Obes Metab"},{"key":"4427_CR45","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/dom.12281","volume":"16","author":"PH Groop","year":"2014","unstructured":"Groop PH, Del Prato S, Taskinen MR et al (2014) Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab 16:560\u2013568","journal-title":"Diabetes Obes Metab"},{"key":"4427_CR46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/dom.12461","volume":"17","author":"G Schernthaner","year":"2015","unstructured":"Schernthaner G, Dur\u00e1n-Garcia S, Hanefeld M et\u00a0al (2015) Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab 17:630\u2013638","journal-title":"Diabetes Obes Metab"},{"key":"4427_CR47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2362.2004.01381.x","volume":"34","author":"G Schernthaner","year":"2004","unstructured":"Schernthaner G, Grimaldi A, Di Mario U et al (2004) GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 34:535\u2013542","journal-title":"Eur J Clin Invest"},{"key":"4427_CR48","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","volume":"32","author":"TK Schramm","year":"2011","unstructured":"Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900\u20131908","journal-title":"Eur Heart J"},{"key":"4427_CR49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.12173","volume":"16","author":"AS Abdelmoneim","year":"2014","unstructured":"Abdelmoneim AS, Eurich DT, Gamble JM et al (2014) Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes Obes Metab 16:22\u201329","journal-title":"Diabetes Obes Metab"},{"key":"4427_CR50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","volume":"3","author":"SH Simpson","year":"2015","unstructured":"Simpson SH, Lee J, Choi S et al (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3:43\u201351","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4427_CR51","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-154-10-201105170-00007","volume":"154","author":"JL Gross","year":"2011","unstructured":"Gross JL, Kramer CK, Leit\u00e3o CB et al (2011) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 154:672\u2013679","journal-title":"Ann Intern Med"},{"key":"4427_CR52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","volume":"14","author":"K Esposito","year":"2012","unstructured":"Esposito K, Chiodini P, Bellastella G et al (2012) Proportion of patients at HbA1c target. Diabetes Obes Metab 14:228\u2013233","journal-title":"Diabetes Obes Metab"},{"key":"4427_CR53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/dom.12402","volume":"17","author":"JB Buse","year":"2015","unstructured":"Buse JB, Peters A, Russell-Jones D et al (2015) Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab 17:145\u2013151","journal-title":"Diabetes Obes Metab"},{"key":"4427_CR54","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36:2508\u20132515","journal-title":"Diabetes Care"},{"key":"4427_CR55","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diab.32.12.1083","volume":"32","author":"R Prager","year":"1983","unstructured":"Prager R, Schernthaner G (1983) Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance following metformin treatment. Results of a double-blind cross-over study in type II diabetics. Diabetes 32:1083\u20131086","journal-title":"Diabetes"},{"key":"4427_CR56","first-page":"346","volume":"12","author":"R Prager","year":"1986","unstructured":"Prager R, Schernthaner G, Graf H (1986) Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabetes Metab 12:346\u2013350","journal-title":"Diabetes Metab"},{"key":"4427_CR57","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","volume":"49","author":"A Natali","year":"2006","unstructured":"Natali A, Ferrannini E (2006) Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49:434\u2013441","journal-title":"Diabetologia"},{"key":"4427_CR58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","volume":"32","author":"MA Abdul-Ghani","year":"2011","unstructured":"Abdul-Ghani MA, Norton L, Defronzo RA (2011) Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 32:515\u2013531","journal-title":"Endocr Rev"},{"key":"4427_CR59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1479164114542802","volume":"11","author":"G Schernthaner","year":"2014","unstructured":"Schernthaner G, Mogensen CE, Schernthaner GH (2014) The effects of GLP-1 analogues, DPP\u20114 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res 11:306\u2013323","journal-title":"Diab Vasc Dis Res"},{"key":"4427_CR60","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","volume":"170","author":"R Roussel","year":"2010","unstructured":"Roussel R, Travert F, Pasquet B et al (2010) Reduction of Atherothrombosis for continued health (REaCH) registry investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170:1892\u20131899","journal-title":"Arch Intern Med"},{"key":"4427_CR61","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrendo.2015.132","volume":"11","author":"G Schernthaner","year":"2015","unstructured":"Schernthaner G, Schernthaner-Reiter MH (2015) Risk of metformin use in patients with T2DM and advanced CKD. Nat Rev Endocrinol 11:697\u2013699","journal-title":"Nat Rev Endocrinol"},{"key":"4427_CR62","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","volume":"130","author":"BM Scirica","year":"2014","unstructured":"Scirica BM, Braunwald E, Raz I et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130:1579\u20131588","journal-title":"Circulation"},{"key":"4427_CR63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jchf.2014.04.005","volume":"2","author":"DL Weir","year":"2014","unstructured":"Weir DL, McAlister FA, Senthilselvan A et al (2014) Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2:573\u2013582","journal-title":"JACC Heart Fail"},{"key":"4427_CR64","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","volume":"385","author":"F Zannad","year":"2015","unstructured":"Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:2067\u20132076","journal-title":"Lancet"},{"key":"4427_CR65","first-page":"\u25a0","volume":"6","author":"AZ Fu","year":"2016","unstructured":"Fu AZ, Johnston SS, Ghannam A et al (2016) Association between hospitalization for heart failure and Dipeptidyl Peptidase-4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. doi:10.2337\/dc15-0764 [Epub ahead of print]","journal-title":"Diabetes Care"},{"key":"4427_CR66","first-page":"\u25a0","volume":"\u25a0","author":"G Schernthaner","year":"2016","unstructured":"Schernthaner G, Cahn A, Raz I (2016) Is the use of DPP\u20114 inhibitors associated with an increased risk for heart failure \u2013 lessons from SAVOR, EXAMINE and TECOS. Diabetes Care [Epub ahead of print]","journal-title":"Diabetes Care"},{"key":"4427_CR67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","volume":"38","author":"JA Udell","year":"2015","unstructured":"Udell JA, Bhatt DL, Braunwald E et al (2015) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 38:696\u2013705","journal-title":"Diabetes Care"},{"key":"4427_CR68","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/M15-0308","volume":"163","author":"SM Ou","year":"2015","unstructured":"Ou SM, Shih CJ, Chao PW et al (2015) Effects on clinical outcomes of adding Dipeptidyl Peptidase-4 inhibitors versus Sulfonylureas to Metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 163:663\u2013672","journal-title":"Ann Intern Med"},{"key":"4427_CR69","first-page":"\u25a0","volume":"7","author":"J Li","year":"2016","unstructured":"Li J, Tong Y, Zhang Y, Tang L et al (2016) Effects on All-Cause Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes by Comparing Insulin With Oral Hypoglycemic Agent Therapy: A Meta-Analysis of Randomized Controlled Trials. Clin Ther. doi:10.1016\/j.clinthera.2015.12.006 [Epub ahead of print]","journal-title":"Clin Ther"},{"key":"4427_CR70","doi-asserted-by":"crossref","unstructured":"Viscoli CM, Brass LM, Carolei A et al (2014) Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 168:823\u2013829","DOI":"10.1016\/j.ahj.2014.07.016"},{"key":"4427_CR71","doi-asserted-by":"crossref","unstructured":"Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. doi: 10.1056\/NEJMoa1506930","DOI":"10.1056\/NEJMoa1506930"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4427-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-016-4427-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4427-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T20:03:30Z","timestamp":1655496210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-016-4427-3"}},"subtitle":["New hope after the EMPA-REG outcome trial"],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["4427"],"URL":"https:\/\/doi.org\/10.1007\/s00059-016-4427-3","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]}}}